Education
About Us
Working with TipRanks
Follow Us
Dr. Martens Plc (DE:3U2)
FRANKFURT:3U2
3U2 Stock Chart & Stats
€0.72
-€0.09(-9.68%)
At close: 4:00 PM EST
€0.72
-€0.09(-9.68%)
Day’s Range― - ―
52-Week Range€0.49 - €1.11
Previous CloseN/A
Volume0.00
Average Volume (3M)406.00
Market Cap
€725.10M
Enterprise Value€935.48M
Total Cash (Recent Filing)€95.70M
Total Debt (Recent Filing)€397.10M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 28, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding967,343,750
10 Day Avg. Volume2
30 Day Avg. Volume406
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.34
Price to Sales (P/S)0.62
P/FCF Ratio2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.08Price Target Upside49.84% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€8.81M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationDr. Martens produced materially stronger free cash flow with a robust operating cash flow to net income ratio. Durable cash conversion supports reinvestment in DTC, deleveraging and shareholder returns, and provides flexibility to fund product launches and store expansion without relying on external financing.
High Gross MarginA near-65% gross margin reflects persistent brand pricing power and favorable product economics. That structural margin provides a buffer to cover retail and SG&A costs, enabling profitability if the company sustains full-price DTC mix and controls operating expenses over the medium term.
Leverage Reduction And Manageable DebtNotable net debt reduction and moderate leverage (net debt/EBITDA ~2.1x) improve financial resilience. Lower gross debt eases interest exposure and increases strategic optionality for marketing, wholesale partnerships or capex, supporting sustainable recovery without excessive refinancing risk.
Bears Say
Declining Revenue TrendMulti-year revenue contraction signals persistent demand weakness or distribution issues. Reduced top-line scale pressures operating leverage, constrains margin recovery and makes profitable reinvestment harder. Reversing this trend is necessary to restore durable earnings growth and ROI.
Sharp ROE DeclineA collapse in ROE indicates the company is generating far less profit from shareholders' capital, reflecting margin compression and weaker capital efficiency. Persistently low ROE undermines long-term shareholder returns and raises questions about the effectiveness of capital allocation and growth investments.
Product And Regional HeadwindsCore product-line issues and EMEA direct-to-consumer weakness are structural concerns for a brand reliant on boots and regional retail strength. Prolonged softness in key categories or markets forces higher markdowns, impairs full-price mix and adds uncertainty to durable revenue and margin recovery.
Dr. Martens Plc News
3U2 FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest stock price was €0.49 and its highest was €1.11 in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is €725.10M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is May 28, 2026 which is in 83 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on Nov 20, 2025. The company reported -€0.01 earnings per share for the quarter, the consensus estimate of -€0.01 by €0.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc does not currently pay dividends.
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is 0.06.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,343,750 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of -€0.01 in its last earnings report, expectations of -€0.01. Following the earnings report the stock price went up 0.556%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in DE:3U2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.08 (49.84% Upside)
€1.08 (49.84% Upside)
Insider Transactions
Bought Shares
Worth £155.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.87%
12-Months-Change
Fundamentals
Return on Equity
1.23%
Trailing 12-Months
Asset Growth
-6.57%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
3U2 Stock 12 Month Forecast
Average Price Target
€1.08
▲(49.84% Upside)
Technical Analysis
Options Prices
Currently, No data available
---